An engineered nanoplatform inhibiting energy metabolism and lysosomal activity of tumor cells to multiply cisplatin-based chemotherapy

被引:1
|
作者
Jiang, Wei [1 ,3 ]
Tie, Zuoxiu [3 ]
Yu, Chi [2 ]
Chen, Yu [4 ]
Liu, Dan [2 ]
Li, Bin [1 ]
机构
[1] Guangxi Univ Sci & Technol, Med Coll, Dept Biochem & Mol Biol, Liuzhou 545005, Peoples R China
[2] Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Shenyang 110142, Peoples R China
[3] Nanjing Univ, Coll Engn & Appl Sci, MOE Key Lab High Performance Polymer Mat & Technol, Nanjing 210033, Peoples R China
[4] Commonwealth Sci & Ind Res Org CSIRO Mfg, Clayton, Vic 3168, Australia
关键词
Energy metabolism; Cell dormancy; Lysosome; Glutathione; Cisplatin prodrug; DRUG; POLYMER;
D O I
10.1016/j.biomaterials.2023.122354
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Although inhibiting the energy metabolism of tumor cells has become an effective measure to enhance chemotherapy, tumor cells can still escape the lethal effect of chemotherapy by entering a dormancy state with low-energy expenditure. Herein, the glutathione (GSH)-responsive nanoplatform (C-A-D NPs) were constructed to inhibit energy metabolism and lysosomal activity of tumor cells, thereby forcing tumor cells to remain vulnerable to cisplatin. In this system, cisplatin prodrug was reduced to cisplatin by GSH, and D-peptide and apoptozole (Az) were released to inhibit the energy metabolism and autophagy-lysosome pathway of tumor cells. The suppressed autophagy-lysosome pathway prevents tumor cells from entering a low-energy dormancy state, resulting in the loss of resistance to the lethal effect of cisplatin with high-energy expenditure and insufficient energy supply. Such engineered nanoplatform effectively enhances the chemotherapeutic effect of cisplatin by inhibiting intracellular energy metabolism and lysosomal activity, showing great clinical prospects.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Comparison of 4 Cisplatin-based chemotherapy regimes in Chemo-radiotherapy of localized advanced head-neck-tumor
    Bohlen, G.
    Kronemann, S.
    Meyners, T.
    Tribius, S.
    Schroeder, U.
    Hakim, S. G.
    Schild, S. E.
    Dunst, J.
    Rades, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 131 - 131
  • [22] Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy.
    Wibmer, Andreas Georg
    Feldman, Darren R.
    Chen, Carol
    Bromberg, Maria
    Dinh, Paul C.
    Zheng, Junting
    Capanu, Marinela
    Travis, Lois B.
    Vargas, Hebert Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice
    Chen, Rui-Lin
    Wang, Zhen
    Huang, Ping
    Sun, Cai-Hua
    Yu, Wen-Ying
    Zhang, Huan-Huan
    Yu, Chen-Huan
    He, Jia-Qi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 94
  • [24] Successful treatment with modified cisplatin-based chemotherapy duplex for patient with renal failure treated with hemodialysis and advanced ovarian germ cell tumor
    Viridiana, Mendez-Calderillo
    Gerardo, Nunez-Saldana
    ECANCERMEDICALSCIENCE, 2022, 16
  • [25] Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
    Solheim, Olesya
    Skalleberg, Jacob
    Warncke, Torhild
    Orstavik, Kristin
    Trope, Claes
    Fossa, Sophie D.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2019, 98 (02) : 240 - 249
  • [26] Exosomal microRNA-506 inhibits biological activity of lung adenocarcinoma cells and increases sensitivity to cisplatin-based hyperthermia
    Zhang, Kunming
    Sun, Xiwen
    Sun, Weikai
    Wang, Meng
    Han, Fushi
    CELLULAR SIGNALLING, 2022, 100
  • [27] Expression of NHEJ genes in head and neck squamous cell carcinoma is associated with tumor response to 5-fluorouracil and cisplatin-based induction chemotherapy
    Pavon, M.
    Parreno, M.
    Leon, X.
    Cespedes, M. V.
    Casanova, I.
    Navas, L. C.
    Mangues, M. A.
    Quer, M.
    Barnadas, A.
    Mangues, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 328 - 328
  • [28] LONG-TERM NEUROTOXICITY AND RAYNAUD'S PHENOMENON IN PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY FOR MALIGNANT OVARIAN GERM CELL TUMOR.
    Popova, O. Solheim
    Skalleberg, J.
    Warncke, T.
    Orstavik, K.
    Trope, C.
    Fossa, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 937 - 937
  • [29] Tumor infiltrating lymphocytes (TIL) assessment in muscle invasive bladder cancer (MIBC) patients treated with cisplatin-based neoadjuvant chemotherapy (NAC) and surgery
    Chanza, Nieves Martinez
    Hamid, Anis
    Salgado, Roberto
    Gevaert, Thomas
    Maetens, Marion
    Rorive, Sandrine
    Aftimos, Philippe Georges
    Sideris, Spyridon
    Gil, Thierry
    Awada, Ahmad
    Roumeguere, Thierry Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
    Olver, I. N.
    Grimison, P.
    Chatfield, M.
    Stockler, M. R.
    Toner, G. C.
    Gebski, V.
    Harrup, R.
    Underhill, C.
    Kichenadasse, G.
    Singhal, N.
    Davis, I. D.
    Boland, A.
    McDonald, A.
    Thomson, D.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1561 - 1568